Three new clinical trials are pushing GLP-1 drugs well beyond their original use for diabetes and weight loss. Tracked on September 20, 2026, these trials explore tirzepatide's potential for addiction treatment and post-surgery weight management, plus a new GLP-1 drug candidate aimed at both weight loss and gout. If any of these conditions are part of your life or someone else's, these trials may be worth watching as they move toward recruitment.
Mazdutide, a new entrant in the GLP-1 drug class, is being tested in a Phase 4 trial for adults with obesity who also have gout. Combining weight loss and gout treatment in a single trial reflects growing interest in whether GLP-1 drugs can address the metabolic and inflammatory conditions that often occur together in this population. The trial has not yet begun recruiting, so specific outcomes and timelines are not yet available. Readers who manage both obesity and gout may want to watch for updates as this trial moves toward enrollment.
Tirzepatide, already approved for diabetes and weight management, is now being studied in a Phase 2 trial for methamphetamine use disorder. This trial will not begin enrolling patients until October 2026, which gives researchers time to finalize their protocols before testing whether the drug affects addiction in ways similar to its effects on appetite and metabolism. The connection between GLP-1 drugs and substance use disorders is an emerging area of research, and this trial represents one of the more unexpected directions the drug class has taken. Anyone interested in addiction treatment options may want to track this trial as it approaches its enrollment date.
A Phase 3 trial will examine whether tirzepatide can help people who had bariatric surgery and did not lose as much weight as the surgery was expected to produce. Researchers call this suboptimal weight loss after surgery, which means the operation itself did not go far enough, not that anyone did anything wrong. The trial is randomized, double-blind, and placebo-controlled, which are standard features for gathering reliable evidence on whether the drug works better than no treatment at all. Anyone who had bariatric surgery and still has obesity may find this trial particularly relevant once it begins recruiting.
None of these trials have started recruiting patients yet, so readers should not expect immediate access to these treatments. If you are interested in participating in one of these trials once they open, I would suggest speaking with your doctor about eligibility and staying in touch with the trial coordinators listed in each record. These studies also show how quickly the research around GLP-1 drugs is expanding into areas like addiction and post-surgical care. Keeping an eye on updates from GLP1Laws can help you stay informed as these trials progress toward enrollment and, eventually, results.
Key details
A new GLP-1 drug called Mazdutide is now being trialed for both weight loss and gout.
Tirzepatide is being tested for methamphetamine addiction, enrolling from October 2026.
Phase 3 trial will test tirzepatide for people who had surgery and still have obesity.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.